阿鹿
Lv4
490 积分
2024-05-24 加入
-
Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
-
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
1个月前
已完结
-
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
1个月前
已完结
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
-
Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy
2个月前
已完结
-
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success
2个月前
已完结
-
Epidemiology of nasopharyngeal carcinoma: current insights and future outlook
2个月前
已完结
-
Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial
3个月前
已完结
-
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
3个月前
已完结
-
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
3个月前
已完结